{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-006352","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.409419+00:00","generated_at":"2026-05-30T16:45:48.906846+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail","bullets":["Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).","Auditor JP Centurion & Partners reappointed with 10,720,634 votes for.","2024 Stock Incentive Plan not approved: 4,094,117 for, 6,382,176 against.","Reverse stock split (1:2 to 1:10) not approved: 4,371,573 for, 6,378,201 against.","Company alleges former officer/director directed unlawful proxy solicitation affecting Proposals 3&4; board authorized investigation, may pursue litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-006352","json":"https://secwatch.observer/filing/0001477932-24-006352.json","markdown":"https://secwatch.observer/filing/0001477932-24-006352.md","text":"https://secwatch.observer/filing/0001477932-24-006352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/0001477932-24-006352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006352/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:45:48.906846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}